Lithuanian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
vincristine/vėžys
Nuoroda įrašoma į mainų sritį
Puslapis 1 nuo 713 rezultatus
A Phase 1 Study of Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
DesdiBackground:
- Mature T-cell malignancies (TCM) are rare and heterogeneous group of leukemias and lymphomas accounting for 5 to 10% of all lymphomas in the US
- Patients with systemic TCM are most commonly treated with a CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone)-like
Early Detection of Neuropathy and Cognitive Impairment Following Treatment for Haematological Malignancies
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Haematological malignancies can be treated with chemotherapy if the patient tolerates the treatment. However, many patients develop complications during treatment including chemotherapy-induced peripheral neuropathy (CIPN) and/or impaired memory. Even though it is a well-known complication, no gold
Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
PRIMARY OBJECTIVES:
I. To establish the maximum tolerated dose (MTD) of parsaclisib in combination with R-CHOP in newly diagnosed diffuse large B-cell lymphoma (DLBCL). (Phase I) II. To assess the complete metabolic response rate by positron emission tomography (PET) (PET complete response [CR]) of
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
PRIMARY OBJECTIVES:
I. To evaluate whether the addition of vincristine/irinotecan to cyclophosphamide/ carboplatin/etoposide alternating with vincristine/doxorubicin/cyclophosphamide improves the event-free survival (EFS) of patients with newly diagnosed stage 4 diffuse anaplastic Wilms tumor (DAWT)
Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
This first cycle will be used to determine whether the patient can tolerate the chemotherapeutic backbone without developing a DLT. The baseline disease evaluation will be obtained following hematologic recovery from the first cycle of chemotherapy, after which combination therapy with vorinostat
Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATL)
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
PRIMARY OBJECTIVE:
I. To determine the safest and most tolerable dose and schedule of lenalidomide to combine with etoposide, prednisone, vincristine sulfate (Oncovin), cyclophosphamide, and doxorubicin hydrochloride (hydroxydaunorubicin hydrochloride) (EPOCH) chemotherapy in adult T-cell
A Treatment Study Protocol for Participants 1-45 Years With Acute Lymphoblastic Leukaemia
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
ALLTogether is a European clinical treatment study for acute lymphoblastic leukaemia (ALL) in children and young adults. The aims are to improve survival and quality of survival for children and young adults with ALL. In young people, ALL has excellent outcome with an overall survival of about 92%
Diagnostic of Chemotherapy Induced Neuropathy in Children
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Epidemiology and suggested mechanisms involved in pediatric chemotherapy induced neuropathy: Pediatric chemotherapy induced peripheral neuropathy (CIPN) is an early (often occurring within the first three months), potentially severe long-lasting and dose limiting adverse effect of treatment in
Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
PRIMARY OBJECTIVE:
I. To evaluate progression-free survival (PFS) at 12 months of venetoclax (VEN) in combination with chemotherapy and SL-401 (tagraxofusp [TAG]) in patients with newly diagnosed blastic plasmacytoid dendritic cell neoplasm (BPDCN).
SECONDARY OBJECTIVES:
I. To determine the safety
R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma (NHL). Currently, R-CHOP is world-widely used in the first-line treatment for DLBCL. There are about one second of patients suffering relapse and drug resistance. Lenalidomide is an analog of thalidomide, the
DCV in the Treatment of Recurrence and Refractory Childhood Solid Tumors
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Purpose of Phase I:
the main purpose: To evaluate the safety of PLD in combination with cyclophosphamide, vincristine, regenerative, and refractory solid tumors in children, including dose absorption toxicity (DLT)
Secondary purpose:
- determine the appropriate maximum tolerated dose (MTD) and /or
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
PRIMARY OBJECTIVE:
I. To demonstrate that the efficacy of treatment with selumetinib as measured by event-free survival (EFS) is non-inferior compared to treatment with carboplatin/vincristine (CV) in previously-untreated low-grade glioma (LGG) not associated with BRAFV600E mutations or systemic
A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
PRIMARY OBJECTIVES:
I. To evaluate the feasibility of adding daratumumab to dose-adjusted (DA)-EPOCH by assessing the percentage of plasmablastic lymphoma (PBL) patients to complete >= 3 cycles of study treatment per protocol.
SECONDARY OBJECTIVES:
I. To estimate the complete response (CR) rate as
Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Hemangiol, Post Marketing Surveillance Study
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
This study is retrospective, longitudinal, descriptive and observational. Children aged 0 to 1 years hospitalized for introduction of Hemangiol between January 2014 and November 2018 will be included. Patients refuse the use of medical data will be excluded.
The main objective is to describe the
Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu
- Dirba 55 kalbomis
- Žolelių gydymas, paremtas mokslu
- Vaistažolių atpažinimas pagal vaizdą
- Interaktyvus GPS žemėlapis - pažymėkite vaistažoles vietoje (netrukus)
- Skaitykite mokslines publikacijas, susijusias su jūsų paieška
- Ieškokite vaistinių žolelių pagal jų poveikį
- Susitvarkykite savo interesus ir sekite naujienas, klinikinius tyrimus ir patentus
Įveskite simptomą ar ligą ir perskaitykite apie žoleles, kurios gali padėti, įveskite žolę ir pamatykite ligas bei simptomus, nuo kurių ji naudojama.
* Visa informacija pagrįsta paskelbtais moksliniais tyrimais
